Dogwood Therapeutics, Inc.
DWTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DWTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DWTX
Dogwood Therapeutics, Inc. is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, with a lead candidate Halneuron® targeting NaV 1.7 modulation for chronic and acute pain.
Key risk: Cash runway limited
BioSniper Score
Based on 5 of 6 signals
Market Cap
$90.1M
Cash Runway
8.3 moLead Asset
halneuron (Phase 2)
Next Catalyst
Phase2_Topline · Sep 30, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial · 2 catalysts for Dogwood Therapeutics, Inc..
Dogwood Therapeutics, Inc. is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, with a lead candidate Halneuron® targeting NaV 1.7 modulation for chronic and acute pain.
- Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders [sec_mda · as of 2024-11-08].
- The company's pipeline is centered on two mechanistic pillars: NaV 1.7 modulation for pain disorders and combination antiviral therapies targeting reactivated herpes virus mediated illnesses [sec_mda · as of 2024-11-08].
- Lead candidate Halneuron® is a voltage-gated sodium channel blocker, a mechanism known to be effective for reducing pain [sec_mda · as of 2024-11-08].
- As of June 30, 2026, the company had cash and equivalents of $9.6 million and shareholders' equity of $74.9 million, with a net loss of $11.5 million for the period [sec].
- The company had no debt outstanding as of June 30, 2026, following a debt exchange and cancellation agreement in March 2025 [sec_mda · as of 2026-08-14].
What works
- The company has a focused pipeline on two mechanistic pillars (NaV 1.7 modulation and antiviral therapies), targeting distinct pain and fatigue-related disorders [sec_mda · as of 2024-11-08].
- Halneuron® is a non-opioid, voltage-gated sodium channel blocker, a mechanism with established efficacy for pain reduction [sec_mda · as of 2024-11-08].
- The company successfully eliminated all debt through a debt exchange and cancellation agreement in March 2025, resulting in no debt outstanding as of June 30, 2026 [sec_mda · as of 2026-08-14].
What to weigh
- The company is pre-revenue and development-stage, with no approved products or commercial revenue [sec_mda · as of 2024-11-08].
- Cash on hand of $9.6 million as of June 30, 2026 is expected to fund operations only into the fourth quarter of 2026, requiring additional financing to continue clinical trials and operations [sec_mda · as of 2026-08-14].
- The company faces significant uncertainty regarding the timing and costs of clinical trials, regulatory approval, and the ability to secure future financing, which may cause dilution for shareholders [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company focused on pain and fatigue disorders.
“We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders.”
SEC MD&A · November 8, 2024
Halneuron® is a voltage-gated sodium channel blocker for pain.
“Halneuron ® is a voltage-gated sodium channel blocker, a mechanism known to be effective for reducing pain.”
SEC MD&A · November 8, 2024
Cash on hand of $9.6 million as of June 30, 2026.
“We anticipate our cash on hand at June 30, 2026 of approximately $9.6 million will fund”
SEC MD&A · August 14, 2026
No debt outstanding as of June 30, 2026.
“There was no debt outstanding at June 30, 2026 and December 31, 2025.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2026-09-30 · Phase2_Topline · halneuron — Phase 2 Readout: halneuron — First topline data readout for Halneuron® Phase 2 trial; results will inform efficacy and safety profile.
- 2026-12-31 · Phase2_Topline · halneuron — Phase 2 Readout: halneuron — Second topline data readout for Halneuron® Phase 2 trial; results will inform efficacy and safety profile.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $9.6M as of June 30, 2026 is expected to fund operations only into Q4 2026, requiring additional financing [sec_mda · as of 2026-08-14].
- Pre-revenue stage — Company is pre-revenue and development-stage with no approved products or commercial revenue [sec_mda · as of 2024-11-08].
- Clinical trial uncertainty — Duration, costs, and timing of clinical trials are uncertain; regulatory approval is not guaranteed [sec_mda · as of 2026-03-18].
- Dilution risk from financing — Future financing through equity or equity-linked securities will cause shareholder dilution [sec_mda · as of 2026-05-15].
What to watch
- Phase 2 topline data readout for Halneuron® expected in Q4 2026 (catalyst timeline).
- Ability to secure additional financing to extend cash runway beyond Q4 2026 [sec_mda · as of 2026-08-14].
- Progress in clinical trials for NaV 1.7 modulation and antiviral therapy programs [sec_mda · as of 2024-11-08].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Dogwood Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dogwood Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
8.3 months
D/E 0.18 · 0% dilution
Lead: Phase 3
4 candidates
2 upcoming, next in ~31d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 0.6%
- Days to cover
- 0.9
- Shares short
- 70,605
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DWTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Dogwood Therapeutics, Inc.?
Dogwood Therapeutics, Inc. is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, with a lead candidate Halneuron® targeting NaV 1.7 modulation for chronic and acute pain.
What is Dogwood Therapeutics, Inc.'s lead drug candidate?
Dogwood Therapeutics, Inc.'s most advanced tracked candidate is halneuron (Phase 2) for Chemotherapy Induced Neuropathic Pain.
What is Dogwood Therapeutics, Inc.'s next catalyst?
Dogwood Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: halneuron" — expected September 30, 2026.
Who is the CEO of Dogwood Therapeutics, Inc.?
Mr. Gregory Duncan is the chief executive officer of Dogwood Therapeutics, Inc. (DWTX).
Where is Dogwood Therapeutics, Inc. headquartered?
Dogwood Therapeutics, Inc. (DWTX) is headquartered in Alpharetta, GA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.